Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) – Equities research analysts at Oppenheimer Holdings cut their FY2017 EPS estimates for shares of Zynerba Pharmaceuticals in a note issued to investors on Tuesday. Oppenheimer Holdings analyst D. Archila now forecasts that the company will earn ($2.49) per share for the year, down from their previous estimate of ($2.31). Oppenheimer Holdings has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Zynerba Pharmaceuticals’ Q4 2017 earnings at ($0.61) EPS, FY2018 earnings at ($2.06) EPS, FY2019 earnings at ($1.66) EPS, FY2020 earnings at ($1.22) EPS and FY2021 earnings at ($1.13) EPS.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its earnings results on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.05). During the same period in the prior year, the company posted ($0.67) EPS.
Shares of Zynerba Pharmaceuticals (ZYNE) opened at $13.88 on Friday. Zynerba Pharmaceuticals has a one year low of $5.42 and a one year high of $25.95.
In related news, major shareholder Michael Rapp acquired 44,255 shares of Zynerba Pharmaceuticals stock in a transaction dated Thursday, October 19th. The shares were purchased at an average price of $9.59 per share, for a total transaction of $424,405.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.02% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its position in shares of Zynerba Pharmaceuticals by 230.7% during the third quarter. Perceptive Advisors LLC now owns 130,700 shares of the company’s stock valued at $1,320,000 after buying an additional 230,700 shares during the last quarter. Cowen Inc. bought a new stake in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $167,000. RTW Investments LP bought a new stake in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $1,672,000. Granite Point Capital Management L.P. raised its position in shares of Zynerba Pharmaceuticals by 47.9% during the third quarter. Granite Point Capital Management L.P. now owns 200,000 shares of the company’s stock valued at $1,672,000 after buying an additional 64,800 shares during the last quarter. Finally, Engineers Gate Manager LP bought a new stake in shares of Zynerba Pharmaceuticals during the third quarter valued at approximately $263,000. Hedge funds and other institutional investors own 34.72% of the company’s stock.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.